These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37216280)

  • 1. Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication.
    Murai J; Ceribelli M; Fu H; Redon CE; Jo U; Murai Y; Aladjem MI; Thomas CJ; Pommier Y
    Mol Cancer Ther; 2023 Aug; 22(8):985-995. PubMed ID: 37216280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.
    Murai J; Thomas A; Miettinen M; Pommier Y
    Pharmacol Ther; 2019 Sep; 201():94-102. PubMed ID: 31128155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes.
    Onji H; Murai J
    Cancer Sci; 2022 Sep; 113(9):2943-2951. PubMed ID: 35766436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.
    Benamar M; Guessous F; Du K; Corbett P; Obeid J; Gioeli D; Slingluff CL; Abbas T
    EBioMedicine; 2016 Aug; 10():85-100. PubMed ID: 27333051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
    Murai J; Feng Y; Yu GK; Ru Y; Tang SW; Shen Y; Pommier Y
    Oncotarget; 2016 Nov; 7(47):76534-76550. PubMed ID: 27708213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
    Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
    Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
    Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
    Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SLFN11 Blocks Stressed Replication Forks Independently of ATR.
    Murai J; Tang SW; Leo E; Baechler SA; Redon CE; Zhang H; Al Abo M; Rajapakse VN; Nakamura E; Jenkins LMM; Aladjem MI; Pommier Y
    Mol Cell; 2018 Feb; 69(3):371-384.e6. PubMed ID: 29395061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq.
    Takashima T; Sakamoto N; Murai J; Taniyama D; Honma R; Ukai S; Maruyama R; Kuraoka K; Rajapakse VN; Pommier Y; Yasui W
    Virchows Arch; 2021 Mar; 478(3):569-579. PubMed ID: 32474729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers.
    Zhang B; Ramkumar K; Cardnell RJ; Gay CM; Stewart CA; Wang WL; Fujimoto J; Wistuba II; Byers LA
    Br J Cancer; 2021 Nov; 125(10):1333-1340. PubMed ID: 34294893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.
    Taniyama D; Sakamoto N; Takashima T; Takeda M; Pham QT; Ukai S; Maruyama R; Harada K; Babasaki T; Sekino Y; Hayashi T; Sentani K; Pommier Y; Murai J; Yasui W
    Cancer Sci; 2022 Feb; 113(2):784-795. PubMed ID: 34808009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress.
    Murai J; Zhang H; Pongor L; Tang SW; Jo U; Moribe F; Ma Y; Tomita M; Pommier Y
    Cell Rep; 2020 Mar; 30(12):4137-4151.e6. PubMed ID: 32209474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer.
    Scattolin D; Maso AD; Ferro A; Frega S; Bonanno L; Guarneri V; Pasello G
    Cancer Treat Rev; 2024 Jul; 128():102768. PubMed ID: 38797062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The crucial role of single-stranded DNA binding in enhancing sensitivity to DNA-damaging agents for Schlafen 11 and Schlafen 13.
    Fujiwara K; Maekawa M; Iimori Y; Ogawa A; Urano T; Kono N; Takeda H; Higashiyama S; Arita M; Murai J
    iScience; 2023 Dec; 26(12):108529. PubMed ID: 38125019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.
    Isnaldi E; Ferraioli D; Ferrando L; Brohée S; Ferrando F; Fregatti P; Bedognetti D; Ballestrero A; Zoppoli G
    Breast Cancer Res Treat; 2019 Sep; 177(2):335-343. PubMed ID: 31222709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
    Winkler C; Armenia J; Jones GN; Tobalina L; Sale MJ; Petreus T; Baird T; Serra V; Wang AT; Lau A; Garnett MJ; Jaaks P; Coker EA; Pierce AJ; O'Connor MJ; Leo E
    Br J Cancer; 2021 Mar; 124(5):951-962. PubMed ID: 33339894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic understanding of human SLFN11.
    Metzner FJ; Wenzl SJ; Kugler M; Krebs S; Hopfner KP; Lammens K
    Nat Commun; 2022 Sep; 13(1):5464. PubMed ID: 36115853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy.
    Kagami T; Yamade M; Suzuki T; Uotani T; Tani S; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Baba S; Sugimura H; Murai J; Pommier Y; Furuta T
    BMC Cancer; 2020 Nov; 20(1):1123. PubMed ID: 33218331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.
    Winkler C; King M; Berthe J; Ferraioli D; Garuti A; Grillo F; Rodriguez-Canales J; Ferrando L; Chopin N; Ray-Coquard I; Delpuech O; Rinchai D; Bedognetti D; Ballestrero A; Leo E; Zoppoli G
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (
    Tang SW; Thomas A; Murai J; Trepel JB; Bates SE; Rajapakse VN; Pommier Y
    Clin Cancer Res; 2018 Apr; 24(8):1944-1953. PubMed ID: 29391350
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.